Across TCGA pan-cancer cohorts, LYRM7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LYRM7 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LYRM7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LYRM7 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where LYRM7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.516	0.781	.004	36	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	19	view →
PDAC	DFS	Median	III,IV	0.163	0.484	.024	11	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.797	.020	4	view →
UCEC	OS	Median	All	0.809	0.974	.011	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: LYRM7 tumor-vs-normal RNA expression · all LYRM7 data types